Literature DB >> 11727961

Clinical relevance of biologic factors in male breast cancer.

M E Meijer-van Gelder1, M P Look, J Bolt-de Vries, H A Peters, J G Klijn, J A Foekens.   

Abstract

There is ample information on the clinical role of biologic factors in female breast cancer: urokinase-type plasminogen activator (uPA), its receptor uPAR, its inhibitors PAI-1 and PAI-2, cathepsin D and pS2-protein. However such reports are missing or very rare for male breast cancer. We determined the cytosolic levels of oestrogen receptor (ER), progesterone receptor (PgR), cathepsin D, pS2-protein, uPA, uPAR, PAI-1 and PAI-2 of the primary tumour tissues from 40 male breast cancer patients. The tumour levels were compared with those of 180 matched females and 4114 historic females with breast cancer. In male breast tumours the level of PgR was higher, those of uPA, PAI-1, PAI-2 and cathepsin D lower. The tumour level of ER in men was similar to those in the matched and postmenopausal women, but much higher than those in the historic women. Male breast cancer seems to be biologically different from female breast cancer. Correlation of the eight cell biologic factors with disease outcome showed that PAI-1 (p = 0.03) was the only independent predictive factor for poor prognosis in male breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11727961     DOI: 10.1023/a:1012221921416

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  13 in total

Review 1.  Sentinel node detection in pre-operative axillary staging.

Authors:  Giuseppe Trifirò; Giuseppe Viale; Oreste Gentilini; Laura Lavinia Travaini; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-22       Impact factor: 9.236

2.  Endocrine therapy for male breast cancer: rates of toxicity and adherence.

Authors:  H Visram; F Kanji; S F Dent
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

3.  The Management and Outcomes of Male Breast Cancer.

Authors:  Ömer Uslukaya; Metehan Gümüş; Hatice Gümüş; Zübeyir Bozdağ; Ahmet Türkoğlu
Journal:  J Breast Health       Date:  2016-10-01

4.  Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases.

Authors:  Tingting Liu; Zhongsheng Tong; Lihong He; Li Zhang
Journal:  Breast Care (Basel)       Date:  2011-12-20       Impact factor: 2.860

Review 5.  HER2-positive male breast cancer: an update.

Authors:  Laura Ottini; Carlo Capalbo; Piera Rizzolo; Valentina Silvestri; Giuseppe Bronte; Sergio Rizzo; Antonio Russo
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-10-04

Review 6.  Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

Authors:  Gaetano Leto; Francesca M Tumminello; Marilena Crescimanno; Carla Flandina; Nicola Gebbia
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Matched-pair analysis of patients with female and male breast cancer: a comparative analysis.

Authors:  Robert Foerster; Frank G Foerster; Volkhard Wulff; Birgit Schubotz; Dieter Baaske; Matthias Wolfgarten; Walther C Kuhn; Christian Rudlowski
Journal:  BMC Cancer       Date:  2011-08-04       Impact factor: 4.430

8.  Male breast cancer: a review.

Authors:  Is Fentiman
Journal:  Ecancermedicalscience       Date:  2009-03-20

9.  Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases.

Authors:  Ana M Burga; Oluwole Fadare; Ruth A Lininger; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2006-10-13       Impact factor: 4.064

10.  Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy.

Authors:  GianMaria Miolo; Lara Della Puppa; Manuela Santarosa; Clelia De Giacomi; Andrea Veronesi; Ettore Bidoli; Maria Grazia Tibiletti; Alessandra Viel; Riccardo Dolcetti
Journal:  BMC Cancer       Date:  2006-06-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.